Watson Ian T, Haugh Isabel, Gardner Alexis R, Menter M Alan
Texas A&M College of Medicine, Bryan, Texas.
Department of Dermatology, Baylor University Medical Center, Dallas, Texas.
Proc (Bayl Univ Med Cent). 2018 May 9;31(3):347-349. doi: 10.1080/08998280.2018.1460132. eCollection 2018 Jul.
We report the first case of a 34-year-old woman with histiocytoid Sweet syndrome (HSS) that was successfully treated with etanercept. HSS is a rare histological variant of acute febrile neutrophilic dermatosis that was described by Requena et al in 2005. It is distinguished by dermal infiltration by mononuclear cells with a histiocytic morphology. To date there are three reported cases of the use of etanercept in the treatment of classic febrile neutrophilic dermatosis but none targeting this disease variant. Our patient presented with a 6-month history of scattered erythematous papules on the neck, trunk, and upper and lower limbs bilaterally. Clinical findings and histopathological evaluation were highly suggestive of HSS. After 32 months of refractory disease activity, our patient was initiated on a regimen of etanercept 1 mg/kg subcutaneously twice weekly and topical desoximetasone 0.05% ointment twice daily as required. To date, our patient has achieved 37 months of remission.
我们报告了首例使用依那西普成功治疗的34岁组织细胞样Sweet综合征（HSS）女性患者。HSS是急性发热性嗜中性皮病的一种罕见组织学变体，于2005年由Requena等人描述。其特征是真皮有组织细胞形态的单核细胞浸润。迄今为止，有3例使用依那西普治疗经典发热性嗜中性皮病的报道，但尚无针对该疾病变体的报道。我们的患者有6个月的病史，双侧颈部、躯干以及上肢和下肢出现散在的红斑丘疹。临床检查结果和组织病理学评估高度提示为HSS。在疾病活动32个月难治后，我们的患者开始接受依那西普皮下注射1mg/kg、每周两次，以及根据需要每日两次外用0.05%地索奈德软膏的治疗方案。迄今为止，我们的患者已实现37个月的缓解。
